Cover Image

PAPERBACK
$54.00



View/Hide Left Panel

BIND Biosciences/U.S./Rusnano/$25 million

Selecta Biosciences/U.S./Rusnano/$25 million

BIOptics/U.S./Rusnano/$5 million

CardioNova/Russia/Maxwell Biotech/$1–5 million

Hepatera/Russia/Maxwell Biotech/$1–5 million

Infectex/Russia/Maxwell Biotech/$1–5 million

MetaMax/Russia/Maxwell Biotech/$1–5 million

EXAMPLES OF ACTIVITIES OF SPECIAL INTEREST TO RUSNANO:

BIND Biosciences (Cambridge, Mass.): Development in Russia of therapeutic nanoparticles for use in addressing solid tumors, inflammatory, and cardiovascular diseases. http://www.bindbio.com/content/pages/company/aboutrussia.jsp

Selecta Biosciences (Watertown, Mass.): Development in Russia of synthetic vaccine nanoparticles that encapsulate adjuvant and either a T-cell epitope or allergen in a polylactic acid-co-glycolic acid core surrounded by a lipid monolayer and a PEG shell decorated with a B-cell epitope.

Panacela Labs (Buffalo, N.Y.): A 4-year venture between Rusnano ($9 million) and Cleveland BioLabs ($3 million) for an oncology subsidiary.

BiOptix Diagnostics (Boulder, Colo.): Development of a surface plasmon-enhanced interferometer-detector for label-free bioassays.

http://cen.acs.org/articles/90/i16/Russian-Investors-Bankroll-biotech.html?h=1167136384. Accessed July 7, 2012.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement